Malignant peritoneal mesothelioma (MPM) is a primary cancer that arises diffusely from the mesothelial cells lining the peritoneum.
Cytoreduction surgery (CRS) with intraoperative or perioperative high-dose regional chemotherapy has been established as the preferred approach in selected patients.
Hyperthermic intraoperative peritoneal chemotherapy (HIPEC) is another treatment regimen for patients with peritoneal mesothelioma.
In this new medical study article, “Treatment Factors Associated With Long-Term Survival After Cytoreductive Surgery and Regional Chemotherapy for Patients With Malignant Peritoneal Mesothelioma”, we learn what factors affect survival rates for patients who underwent the CRS surgery and the HIPEC regimen.
From the Abstract:
Conclusion: Operative CRS with HIPEC is associated with prolonged survival in patients with [malignant peritoneal mesothelioma (MPM)]. Factors associated with survival include age, complete or near complete gross tumor resection, histologic tumor grade, and HIPEC with cisplatin. Cisplatin (versus mitomycin-C) was independently associated with improved survival and demonstrates a salutary effect for HIPEC with cisplatin in the management of patients with [malignant peritoneal mesothelioma (MPM)].
“The median, actuarial overall survival was 38.4 months’, according to the authors of this article published online March 13, 2013 by the Surgery medical journal (Epub Ahead of Print).
When will continue to watch for new articles about mesothelioma survival and treatment options so that we can report significant findings to you here on Asbestos HUB.
If you know of any developments that we should be reporting on, please leave a Comment below or send me an email.
Asbestos-Mesothelioma Case Evaluation Form
Free. Confidential. No Obligation.